阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌的临床疗效

Clinical efficacy of abiraterone combined with prednisone in the treatment of metastatic castration-resistant prostate cancer

目的 探讨阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌的临床疗效。方法 根据治疗方法的不同将87例转移性去势抵抗性前列腺癌患者分为对照组(n=42)和联合组(n=45),对照组患者采用泼尼松治疗,联合组患者采用阿比特龙联合泼尼松治疗。比较两组患者的临床疗效、实验室指标[前列腺特异性抗原(PSA)、睾酮]及不良反应发生情况。结果 联合组患者的疾病控制率为86.67%(39/45),高于对照组患者的64.29%(27/42),差异有统计学意义(P﹤0.05)。治疗后,两组患者的PSA和睾酮水平均低于本组治疗前,且联合组患者的PSA和睾酮水平均低于对照组,差异均有统计学意义(P﹤0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P﹥0.05)。结论 阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌患者的疗效确切,可降低PSA和睾酮水平,且安全性尚可,临床可考虑将其推广应用。

Objective To investigate the clinical efficacy of abiraterone combined with prednisone in the treatment of metastatic castration-resistant prostate cancer.Method A total of 87 patients with metastatic castration-resistant prostate cancer were divided into control group(n=42,treated with prednisone)and combined group(n=45,treated with abiraterone+prednisone)according to different treatment methods.The clinical efficacy,laboratory indicators[prostate specific antigen(PSA),testosterone]and adverse reactions were compared between the two groups.Result The disease control rate of the combined group was 86.67%(39/45),higher than 64.29%(27/42)of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of PSA and testosterone in the two groups were lower than those before treatment,with lower levels of PSA and testosterone in the combined group than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Abiraterone combined with prednisone is effective in the treatment of patients with metastatic castration-resistant prostate cancer,and can effectively reduce PSA and testosterone levels with moderate safety,which can be considered for clinical application.